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The most common hereditary melanoma susceptibility
disorder is the familial atypical multiple mole-melanoma
(FAMMM) syndrome. FAMMM is regarded as an ideal
natural model to study the very complex pathologic
mechanism of melanoma. In 1994, cloning of the melan-
oma susceptibility gene CDKN2A was thought to give
answers to many questions on genotype-phenotype cor-
relations in familial melanoma. Today, 4 y later, germline
mutations cosegregate with melanoma in only 40%–50%
FAMMM; LINKAGE STUDIES ON CHROMOSOME 1P
The familial occurrence of cutaneous malignant melanoma was already
recognized in 1820 by Norris (1820). The association of familial
melanoma with inherited atypical nevi was originally described as the
BK mole syndrome (Clark et al, 1978), but became more generally
known as the dysplastic nevus (DNS) syndrome and the familial atypical
multiple mole-melanoma (FAMMM) syndrome. It has been estimated
that 8%–12% of melanomas occur in the familial setting (Greene and
Fraumeni, 1979).
In 1982, the Pigmented Lesion Clinic at the Leiden Department of
Dermatology was established to facilitate studies on familial melanoma.
Shortly thereafter, evidence of familial occurrence of melanoma was
found in 18 melanoma patients and today, more than a hundred
families have been registered. Ten of these families have been very
well documented with respect to number of melanoma and atypical
nevi validating the diagnosis of the FAMMM syndrome (Bergman et al,
1992). Most Dutch FAMMM families are from the Leiden region and
live in two towns within a distance of 20 km from the hospital. The
population in these regions has been stationary for several generations
due to their orthodox religion and strong family ties.
In 1983, the first linkage analysis in melanoma families was under-
taken by Greene et al (1983). Using the combination of melanoma
and atypical nevi as the disease phenotype, nonsignificant evidence for
linkage between a melanoma/atypical nevus predisposition gene and
the Rhesus blood group locus on the short arm of chromosome 1 was
supported. In 1989, the same group localized the gene to a more distal
chromosome 1 region between the DNA markers D1S47 and PND
(Bale et al, 1989). Coinciding with this report we published data
excluding all of the short arm of chromosome 1 in six Dutch FAMMM
families (van Haeringen et al, 1989), including the D1S47 and PND
marker region (Gruis et al, 1990). No supporting evidence for a
melanoma and/or nevus susceptibility locus in the latter region was
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of the families predisposed to this disease. The hunt for
genes and modifying genes is on again. Through the
years the very well-characterized Dutch FAMMM families
have proven to be valuable study subjects in melanoma
research. This paper describes over 10 y of melanoma
research illustrated by research performed in the Dutch
FAMMM families. Key words: CDKN2A/hereditary melan-
oma/melanocortin 1 receptor. Journal of Investigative Dermato-
logy Symposium Proceedings 4:50–54, 1999
provided by marker typing in melanoma families from North America
(Cannon-Albright et al, 1990) and Australia (Kefford et al, 1991;
Nancarrow et al, 1992).
CDKN2A, A MELANOMA SUSCEPTIBILITY GENE ON
CHROMOSOME 9P
In 1992, Cannon-Albright et al (1992) provided highly significant
evidence for a melanoma susceptibility locus in the chromosomal
region 9p13-p22. In their analysis, only patients with melanoma were
considered as affected, ignoring the occurrence of atypical nevi. Two-
point and multipoint linkage analysis in Dutch (Gruis et al, 1993,
1995a; Bergman et al, 1994), Australian (Nancarrow et al, 1993), and
British (MacGeoch et al, 1994) FAMMM kindreds confirmed the
localization of the melanoma locus. Analysis of the American families
earlier found to be linked to chromosome 1, now suggested that some
of them are linked to chromosome 9 as well (Goldstein et al,
1996), although a number of families continues to show linkage to
chromosome 1.
In a very short period of time, an interesting candidate gene for
melanoma susceptibility was cloned from the 9p21 region (Kamb et al,
1994b; Nobori et al, 1994). The gene product had been earlier
identified as the cyclin-dependent kinase inhibitor, p16 (Serrano et al,
1993). The p16 gene has been variably called MTS1, INK4A, and
CDK4I; nowadays CDKN2A is the most accepted nomenclature. The
CDKN2A gene is a key player in cell cycle regulation (Serrano et al,
1993). The gene encodes the p16 protein that binds and inhibits cyclin
dependent kinase (CDK) 4 and 6, an inhibition that prevents complex
formation of CDK4 with cyclin D1. The CDK4/cyclin D complex
normally supports the transition from G1 to S phase in the cell cycle
by phosphorylating and inactivating the retinoblastoma gene product.
Homozygous deletions and mutations of CDKN2A in cell lines and
primary tumors of several tumor types support a general tumor
suppressor function for the CDKN2A gene (Kamb et al, 1994a;
Weaver-Feldhaus et al, 1994; Gruis et al, 1995c; Liu L et al, 1995).
CDKN2A, THE MAJOR MELANOMA GENE
Support for the role of the CDKN2A in melanoma predisposition was
additionally provided by the identification of germline mutations in
affected members of melanoma kindreds all over the world (Gruis et al,
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1995b; Hussussian et al, 1994; Liu Q et al, 1995; Harland et al, 1997;
Pollock et al, 1998). Germline mutations in CDKN2A are typically
point mutations, insertions, or small intragenic deletions within the
first or second exon and are present in approximately 40%–50% of the
9p-linked melanoma families studied (Foulkes et al, 1997).
In most of the Dutch FAMMM families a 19 bp germline deletion
(p16-Leiden) in exon 2 of the CDKN2A gene was observed in
melanoma patients (Gruis et al, 1995b). The deletion introduces a
frameshift resulting in a truncated p16 protein. Consequently, two of
the four ankyrin domains of p16, by which p16 binds to CDK4, are
disrupted by the deletion. All families in which the deletion has been
observed came from the same geographic area of the Netherlands and
carried the same 9p21 haplotype. A common founder for these families
was observed in the year 1707 (Hille et al, 1998).
Of potential importance regarding the role of p16 in the development
of melanoma was the discovery of two individuals within one of the
Dutch melanoma kindreds with germline deletions in both copies of
CDKN2A (Gruis et al, 1995b). Surprisingly, one of these human
‘‘knock-outs’’ did not develop melanoma prior to her death at the age
of 55 from an adenocarcinoma. The presence of three very mildly
atypical nevi was the only sign possibly related to FAMMM. Her
progeny had the classic FAMMM phenotype, with melanomas and
atypical nevi present in two of her three children. On the contrary,
the other homozygous individual developed atypical moles in very
large numbers at the age of 11. Already at the age of 15, he developed
a melanoma in situ and an invasive melanoma. Our observation of
normal development in the absence of functional p16 implies that p16
is not sufficient to develop melanoma. Either other endogenous or
exogenous factors or the presence of functionally redundant genes
seems to be required for phenotypic expression.
ADDITIONAL CELL CYCLE REGULATORS AS CANDIDATE
GENES FOR MELANOMA
In conjunction with the cloning of the CDKN2A gene from the 9p21
region, a gene with 93% sequence homology to the CDKN2A gene
was cloned 30 kb downstream of CDKN2A (Kamb et al, 1994a). This
CDKN2B gene encodes p15; another inhibitor of CDK4. CDKN2B
is often found to be codeleted together with the CDKN2A gene in
many tumor cell lines, including melanoma (Suzuki et al, 1995; Stadler
and Olopade, 1996; Jadayel et al, 1997; Hamada et al, 1998; Walker
et al, 1998). The latter suggests that p15 may be a tumor suppressor as
well. Ectopic expression of p15 inhibits growth of tumor-derived cell
lines, although lack of p15 mutations in tumor cell lines and in 9p21-
linked melanoma kindreds suggests a role for p15 in growth regulation,
but a limited role for p15 in tumor progression (Liu et al, 1997; Stone
et al, 1995).
P16 regulates passage through the G1 checkpoint of the cell cycle
by CDK4/cyclinD1 and CDK6/cylinD1 kinases that phosphorylate
the retinoblastoma protein. This negative regulatory pathway suggests
several other candidates for examination in not 9p-linked melanoma
kindreds. Today, in two unrelated melanoma families who do not carry
p16 germline mutations, an Arg24Cys mutation in the CDK4 gene
has been observed that averts binding of the p16 protein to CDK4
(Zuo et al, 1996). In one other 9p-linked melanoma kindred a Arg24His
mutation was observed (Soufir et al, 1998). Despite the strong evidence
that CDK4 can be considered a second familial melanoma gene, the
very low frequency of CDK4 mutations in melanoma kindreds suggests
that additional genes play a role in the development of familial
melanoma.
New light may be shed on the role of the CDKN2A gene in tumor
development by the recent finding of a second protein product of the
CDKN2A gene (p14ARF, p19ARF in the mouse), which originates
from an unrelated exon of CDKN2A (exon 1β) spliced onto exon 2
in an alternate reading frame. P16 is a recognized tumor suppressor
that induces a G1 cell cycle arrest by inhibiting the phosphorylation
of the retinoblastoma protein by the cyclin-dependent kinases, CDK4
and CDK6. The product of the human CDKN2A β transcript,
p14ARF, activates a p53 response that manifests in elevated levels of
MDM2 and p21(CIP1) and in cell cycle arrest in both G1 and G2/M
Figure 1. Schematic representation of the role of the p16 and p14ARF
proteins in cell cycle regulation. P16 and p14ARF restrain cell growth by
affecting the functions, the retinoblastoma protein and p53, respectively.
Figure 2. Schematic representation of the different CDKN2A and
p14ARF transcripts obtained in the wild-type situation and in the case
of a 19 bp deletion of exon 2 (p16-Leiden and p14ARF-Leiden). At the
position of the deletion in exon 2 (as depicted by a black triangle) the reading
frame is changed for both the CDKN2A and the p14ARF transcript. The
p14ARF transcript is followed by the CDKN2A transcript at the point of
the deletion.
(Kamijo et al, 1997, 1998; Stott et al, 1998) (Fig 1). P14ARF acts by
binding directly to both p53 and MDM2, resulting in the stabilization
of p53 and MDM2. Conversely, p53 negatively regulates p14ARF
expression and there is an inverse correlation between p14ARF
expression and p53 function in human tumor cell lines. p14ARF
expression, however, is not involved in the response to DNA damage.
Binding of the p14ARF N-terminal domain to p53 (encoded by
CDKN2A exon 1β) seems to be necessary and sufficient to induce
cell cycle arrest (Quelle et al, 1997). These results place p14ARF in
an independent pathway upstream of p53, and imply that CDKN2A
encodes two proteins that are involved in tumor suppression.
Until now, no germline mutations have been observed in the first
exon (exon 1β) of p14ARF in melanoma families (FitzGerald et al,
1996; Liu et al, 1997), although germline mutations observed in
CDKN2A exon 2 might effect both p16 and p14ARF function due
to the dual utilization this exon (FitzGerald et al, 1996). Frameshift
mutations have the potential to produce chimeric proteins. A potential
of chimeric protein productions is nicely illustrated in the Dutch
FAMMM families in which a 19 bp deletion in exon 2 of CDKN2A
leads to a frameshift yielding a transcript encoding the N-terminal half
of p14ARF fused to the C-terminal half of p16 (Fig 2). The generated
fusion protein shows no binding capacity to CDK4 or CDK6 (Dr. G.
Peters, personal communication). Data on the p14ARF-related function
of the protein are required.
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MODIFICATION OF MELANOMA RISK BY
POLYMORPHISMS IN THE MELANOCYTE-STIMULATING
HORMONE RECEPTOR GENE
Whereas one of the major risk factors for skin cancer, ultraviolet
radiation, is environmental (Armstrong and Kricker, 1996), the other
major determinant of skin cancer, namely the pigmentary status of the
individual, is definitely genetic (Armstrong and Kricker, 1996). Murine
genetics has proven to be a powerful tool to study the genetics of
pigmentation. The identification of the murine extension locus as the
human melanocortin 1 receptor (MC1R) (Mountjoy et al, 1992;
Robbins et al, 1993) stimulated human studies of the cutaneous response
to ultraviolet radiation. MC1R is a seven transmembrane domain G
protein-coupled receptor encoded by the MC1R gene on chromosome
16q24.3 (Gantz et al, 1994). The natural agonist of the MC1R is
α-melanocyte stimulating hormone that acts via MC1R to increase
the synthesis of eumelanin (brown/black pigment) in melanocytes
(Hunt et al, 1995).
In analogy with, for example, mice, foxes, and cattle, where variants
of MC1R are associated with various coat colors (Robbins et al, 1993;
Joerg et al, 1996; Vage et al, 1997), in humans, variants in MC1R have
been linked with sun-sensitive skin types (Valverde et al, 1995) and in
addition melanoma susceptibility (Valverde et al, 1996). Valverde et al
(1995) showed that polymorphisms within the MC1R coding region
turned out to be present in 80% of individuals of a predominantly
British population with red hair and/or fair skin that tans poorly. Their
results suggested that MC1R is a control point in the regulation of
pigmentation phenotype and that amino acid variations in the MC1R
protein are associated with a poor tanning response. A major drawback
of this study was that individuals were selected from the extremes of
hair color or skin type, providing no adequate basis for risk calculations
or mode of inheritance studies on pigmentary phenotype.
In a consecutive series of Irish volunteers the contribution of MC1R
variants to pigmentation was furthermore substantiated (Smith et al,
1998). Seventy-five per cent of the study group contained a MC1R
sequence variant in the gene, with 30% containing two variants.
MC1R variants seemed to be associated with red-haired individuals in
this Irish population in which three variants in particular, Arg151Cys,
Arg160Trp, and Asp294His, showed over-representation. The very
same variants were also over-represented in individuals with fair skin.
The presence of one of these variants as homozygous or compound
heterozygous in red-haired individuals suggests a possible Mendelian
recessive inheritance for red hair. Follow up of the Asp294His variant
in 57 subjects with nonmelanoma skin cancer from a UK population
showed a significantly increased frequency of this variant in this study
group. Again, one should realize that in this study design, the MC1R
gene has not been checked for all possible variants present. In the
cancer study group, individuals were only screened for the presence
of the Asp294His variant without analysis for additional variants.
The association between MC1R coding region variations
Arg151Cys, Arg160Trp and Asp294His and red hair was confirmed in
a study of Australian monozygotic and dizygotic twins (Box et al,
1997). In addition to the study of Valverde et al (1995), the variant
Val60Leu was more apparent in fair/blonde and light brown hair
colors. Although no variant by itself was associated with any skin type,
studies on MC1R genotypes showed a strong association with hair
color and skin type when allowing for any two MC1R variants in the
genotype. Both studies clearly demonstrate that human red hair color
is associated with variant MC1R alleles, although discordance for red
hair color in dizygotic twins, who both share MC1R haplotypes,
suggests that variants in MC1R are necessary but not sufficient for
red hair.
The link of MC1R variants with sun-sensitive skin types suggests
the MC1R gene to be a susceptibility candidate for melanoma. Valverde
et al (1996) compared the frequency of earlier described MC1R gene
variants (Valverde et al, 1995) in 43 unrelated melanoma patients and
44 controls. MC1R variants were more common in cases than controls,
resulting in a relative risk of 3.91 for melanoma (95% confidence
interval 1.48–10.35). Of note, the Asp84Glu variant turned out to
present in melanoma cases, although the contribution of variant MC1R
alleles in melanoma cases was largely independent of skin type,
suggesting a more causal role for MC1R in melanoma development.
Associations of MC1R variants with skin type, hair color, and
melanoma susceptibility were followed up in a large case-control study
of 306 melanoma cases and 190 controls (Ichii-Jones et al, 1998).
Unfortunately, only the frequency of the Val92Met, Asp294His, and
Asp84Glu alleles has been determined. The allele frequencies of the
three variants observed in melanoma cases were not different from the
frequencies experienced in the control population. Within the cases
and control group, the frequency of studied alleles turned out to be
similar in skin type I and II individuals compared with individuals
with skin types III and IV. In conjunction with earlier studies (Valverde
et al, 1995; Box et al, 1997), an association was found between skin
type and the presence of one or two variant alleles in the genotype of
control individuals. Unexpectedly, although not significantly proven,
the presence of one or more variant alleles in the genotype in cases
was associated with tanning rather than burning of the skin. The earlier
observed association of MC1R variants and hair type could not be
observed in any of the variants under study in either cases or controls.
Therefore, in this study the variants Val92Met, Asp294His, and
Asp84Glu were not considered to be major determinants of skin type
or melanoma risk.
At the moment, the Leiden Skin Cancer Study has started in which
we explore the relationship between sun exposure, pigmentary traits,
and MC1R variants in a large case control study, including pigmented
and nonpigmented skin cancer. In addition, MC1R variant studies in
Dutch FAMMM families are on their way to explore the modifying
effect of MC1R variants on melanoma risk.
The discrepancies between the studies might relate to population-
based differences in allele frequencies, the numbers of controls used,
or selection of the controls. Studies of the functional significance of
the various alleles might shed light on the real involvement of MC1R
variants in pigmentation phenotype or melanoma development. The
position of the Val92Met variant in the second trans membrane domain
of the receptor was thought to alter the α-helix structure of the second
transmembrane domain; however, the finding that the receptor ligand
α-melanocyte stimulating hormone (α-MSH) has a slightly reduced
affinity (5% less) for its receptor (Xu, 1996) suggests that the Val92Met
variant is a neutral polymorphism that does not affect the relative
amounts of eumelanin and pheomelanin produced. Both the Val92Met
and the Asp84Glu variant have been expressed in heterologous cells
to measure changes in intracellular cAMP in response to α-MSH.
Again, neither of these variants show significant changes from the
wild-type response (Koppula et al, 1997). The Arg151Cys variant seems
more obviously to affect receptor functioning. This variant is located
in the second intracellular domain in a consensus sequence for cAMP-
dependent protein kinase. This change might block phosphorylation
and hence receptor signaling.
GENETICS OF FAMILIAL MELANOMA, HOW FAR HAVE
WE COME?
Identification of germline mutations within the CDKN2A gene in
melanoma families has been a considerable step forward in the field of
melanoma genetics. Despite this major discovery, CDKN2A seems to
be related to melanoma in only 40% of 9p-linked melanoma families.
This relatively small proportion suggests that mutations outside the
coding region or other nearby located genes are responsible for
melanoma susceptibility. Loss of coordinate expression of the CDKN2A
and p14ARF transcripts may be an alternative genetic basis for
melanoma susceptibility in certain 9p-linked kindreds. Rizos et al
(1997) analyzed allele-specific expression levels of both the CDKN2A
and the p14ARF transcripts in B-lymphoblastoid cells from 18 members
of hereditary melanoma kindreds, including four unrelated control
individuals. In 15 of the 18 individuals examined, steady-state levels
of each transcript either originated equally from each parental chromo-
some, or one parental chromosome was dominant for both transcripts.
In three affected members of two 9p-linked kindreds without exonic
CDKN2A mutations, however, this pattern of coordinate expression
was disrupted. In these individuals there was underexpression of the
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p14ARF transcript, relative to the CDKN2A transcript, from the
chromosome segregating with disease susceptibility. Methylation of
the 59 CpG island of the CDKN2A tumor suppressor gene has proven
to be a commonly used mechanism of inactivation of this cell cycle
regulatory gene in many tumor types (Herman et al, 1995). Although
methylation-associated gene silencing seems not to represent a common
mechanism for CDKN2A inactivation in sporadic melanoma (Gonzalgo
et al, 1997).
Apart from the absence of germline mutations in 9p-linked families,
the relationship between the CDKN2A gene and the second clinical
phenotype of the FAMMM syndrome, atypical nevi (AN) remains
unresolved. Inclusion of patients with over 10 AN and melanoma in
the linkage analysis in Dutch FAMMM families increased the 9p-
linked lod score (Gruis et al, 1993). Lower numbers of AN diminished
the lod score. In addition to these results, the presence of many
FAMMM family members in Dutch as well as American families with
numerous AN without mutations in the CDKN2A gene, implies the
existence of additional genes for the predisposition and development
of AN. Identification of genomic regions that show increased sharing
(identity by descent) by the nevus patients in the very stationary
Dutch FAMMM families are now underway to localize and identify
these genes.
Therefore, 6 y after the localization of a melanoma locus on
chromosome 9p, a new field of research has opened up the search
for additional melanoma genes, nevus genes, interactions between
melanoma genes and modifying genes, and interactions between
melanoma genes and environmental factors to explain the complex
character of melanoma genetics.
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